Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | IAPP | P10997 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130941 | 0.84 | PDPK1 (0.61) | PDPK1FFAR1FFAR4NPC1 | |
| SCHEMBL30437759 | 0.84 | PDPK1 (0.61) | PDPK1FFAR1FFAR4NPC1 | |
| SCHEMBL3515626 | 0.83 | PDPK1 (0.56) | PDPK1MTNR1BFFAR1DGAT1FFAR4 | |
| SCHEMBL26938435 | 0.83 | PDPK1 (0.56) | PDPK1MTNR1BFFAR1DGAT1FFAR4 | |
| SCHEMBL30488619 | 0.82 | MAOB (0.53) | FFAR1FFAR4CHRNA7IAPP | |
| SCHEMBL21222818 | 0.82 | MAOB (0.53) | FFAR1FFAR4CHRNA7IAPP | |
| SCHEMBL8444 | 0.82 | DGAT1 (0.46) | PDPK1MTNR1BDGAT1PYCR1AKR1B1 | |
| SCHEMBL2130306 | 0.82 | PDPK1 (0.52) | PDPK1MTNR1BNPC1AKR1B1P2RX7 | |
| SCHEMBL1404941 | 0.81 | CHRNA7 (0.62) | FFAR1FFAR4CHRNA7IAPP | |
| SCHEMBL29837823 | 0.80 | CYP4F2 (0.50) | PDPK1MTNR1BFFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911643-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-2970235-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9512115-B2 | Inhibitors | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512115-B2 | Inhibitors | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160031869-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20160031869-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-04 | — | — | US | disclosed |
| WO-2014140279-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-7553604-B2 | Cyanine compound, optical recording material, and optical recording medium | ADEKA CORPORATION (JP) | 2009-06-30 | — | — | US | disclosed |
| EP-1505125-B1 | Cyanine compound, optical recording material, and optical recording medium | ADEKA CORP (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20050031993-A1 | Cyanine compound, optical recording material, and optical recording medium | ASAHI DENKA CO., LTD. (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1505125-A1 | Cyanine compound, optical recording material, and optical recording medium | Asahi Denka Co., Ltd. (JP) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031869-A1 | NOVEL INHIBITORS | GLS, GLUL, QPCT | PDPK1 1661/4885MTNR1B 3246/4885FFAR1 2805/4885 |
| US-20050031993-A1 | Cyanine compound, optical recording material, and optical recording medium | CHRM1, KCNB1, KCNB2 | PDPK1 3541/4885MTNR1B 368/4885FFAR1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.